A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down From a Maintenance Therapy With RELVAR Inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects

Trial Profile

A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down From a Maintenance Therapy With RELVAR Inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Fluticasone furoate (Primary) ; Fluticasone propionate; Vilanterol/fluticasone furoate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2015 Planned End Date changed from 1 Oct 2015 to 1 Aug 2015, as reported by ClinicalTrials.gov.
    • 05 Apr 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Aug 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top